KB Home
KBH
D.R. Horton
DHI
Lennar Corp
LEN
Meritage Homes
MTH
Ecopetrol
EC
US Stock MarketDetailed Quotes
HLVX HilleVax
- 1.880
- +0.060+3.30%
Close Mar 6 16:00 ET
- 1.880
- 0.0000.00%
Post 20:01 ET
93.64MMarket Cap-0.61P/E (TTM)
1.910High1.810Low167.01KVolume1.830Open1.820Pre Close311.78KTurnover0.55%Turnover RatioLossP/E (Static)49.81MShares18.41552wk High0.51P/B57.55MFloat Cap1.55052wk Low--Dividend TTM30.61MShs Float24.420Historical High--Div YieldTTM5.50%Amplitude1.550Historical Low1.866Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
HilleVax Stock Forum
📊⚡️📊
On a day that saw its stock plummet by 84%, closing at $2.25, HilleVax, Inc. (Nasdaq: HLVX) announced the topline data results from its NEST-IN1 clinical study. This notable decline followed the announcement that the NEST-IN1 study did not meet its primary or secondary efficacy endpoints, leading the company to discontinue further dev...
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
HilleVax announced topline results from the NEST-IN1 Phase 2b study of HIL-214 in infants. The trial, conducted in the US and Latin America, did not meet its primary or secondary efficacy endpoints. Specifically, the vaccine showed a mere 5% efficacy against moderate or severe acute gastroenteritis caused by norovirus, which was statistically insignificant. Consequently, HilleVax wil...
No comment yet